As of November 6, 2026, Artelo Biosciences, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 8 filings are on record since September 19, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Artelo Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 173,914 · Sole dispositive: 0 · Shared dispositive: 173,914 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Armistice Capital, LLC · Percent: 9.99% · SCHEDULE 13G
- · Holder: Mitchell P. Kopin · Percent: 9.99% · SCHEDULE 13G
- · Holder: Farb Daniel Stuart · Percent: 0.8% · SCHEDULE 13D/A
Artelo Biosciences, Inc. has 8 Schedule 13D or 13G filings on record since 2025-09-19. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 Farb Daniel Stuart
On September 19, 2025, the Reporting Person delivered a letter to the Issuer nominating a slate of highly qualified director candidates, including Daniel S.From Item 4 of the SCHEDULE 13D filed 2025-09-19
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 4.8% | 173,914 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| 0.8% | 16,399 | SCHEDULE 13D/A, 2025-10-21 | 2025-10-20 | |
| Armistice Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Artelo Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Artelo Biosciences, Inc. and the records around it.
Artelo Biosciences, Inc. elsewhere on the record
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Artelo Biosciences, Inc.
Get an email when Artelo Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Artelo Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Artelo Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Artelo Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mitchell P. Kopin | 0 | 173,914 | 0 | 173,914 | SCHEDULE 13G/A, 2026-08-13 |
| Daniel B. Asher | 0 | 173,914 | 0 | 173,914 | SCHEDULE 13G/A, 2026-08-13 |
| Intracoastal Capital LLC | 0 | 173,914 | 0 | 173,914 | SCHEDULE 13G/A, 2026-08-13 |
| Armistice Capital, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Artelo Biosciences, Inc. by CUSIP 04301G706 and gives its principal executive office as 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-19 | Farb Daniel Stuart intent stated | 9.8% | SCHEDULE 13D |
| 2025-10-03 | Farb Daniel Stuart | 7.7% | SCHEDULE 13D/A |
| 2025-10-17 | Farb Daniel Stuart | 7.7% | SCHEDULE 13D/A |
| 2025-10-21 | Farb Daniel Stuart | 0.8% | SCHEDULE 13D/A |
| 2026-04-03 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-08-13 | Mitchell P. Kopin | 4.8% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 0% | SCHEDULE 13G/A |
Also on the record for Artelo Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 6, 2026 | Form D, private offering | $11M sold | Form D page | Source |
| March 27, 2026 | Form D, private offering | $237K sold | Form D page | Source |
| March 27, 2026 | Form D, private offering | $315K sold | Form D page | Source |
| March 27, 2026 | Form D, private offering | $113K sold | Form D page | Source |
| February 6, 2026 | Form D, private offering | $500K sold | Form D page | Source |
| November 10, 2025 | Form D, private offering | $3.72M sold | Form D page | Source |
| August 13, 2025 | Form D, private offering | $9.47M sold | Form D page | Source |
| July 9, 2025 | Form D, private offering | $1.43M sold | Form D page | Source |
Artelo Biosciences, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Artelo Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.